CA: A Cancer Journal for Clinicians最新文献

{"title":"Nonpharmacologic interventions for managing distress, anxiety, and depression for patients with cancer and their family caregivers: A systematic review and meta-analysis","authors":"Lisa C. Schiess, Lixin L. Song, Sabine Schädelin, Thomas Fürst, Corinne Urech, Christopher R. Friese, Maria C. Katapodi","doi":"10.3322/caac.70076","DOIUrl":"https://doi.org/10.3322/caac.70076","url":null,"abstract":"As more cancer treatments take place in outpatient settings, family caregivers provide essential care and emotional support over long periods. Unaddressed patient and caregiver psychological distress can lead to worse outcomes, reflecting the challenges of managing complex care demands in the home setting. This systematic review and meta-analysis examined how well nonpharmacologic interventions (NPIs) reduce distress, anxiety, and depression in adult patients with solid tumors and their family caregivers. The authors included 68 randomized controlled trials (RCTs) with a total of 11,987 participants. NPIs were characterized as psychoeducation, therapeutic counseling, skills training, or behavior modification. By using random-effects models (Hedges g), they observed that NPIs significantly reduced patient distress at both 0.0–3.0 months (g = 0.13) and 3.1–6.0 months (g = 0.18), but NPIs did not significantly reduce caregiver distress. In the short term (0.0–3.0 months), NPIs also significantly reduced anxiety (g = 0.31 for patients; g = 0.15 for caregivers) and depression (g = 0.28 for patients; g = 0.25 for caregivers). Subgroup analyses examined the impact of patient and caregiver characteristics along with NPI type, delivery format, dose, and duration. NPIs delivered jointly to patients and caregivers yielded significant effects that were higher compared with NPIs delivered separately. NPIs can help manage distress in patients and reduce anxiety and depression in both patients and caregivers. However, the lack of long-term follow-up limits our understanding of their impact on patients and caregivers with prolonged or delayed psychological symptoms (PROSPERO registration number CRD42024536629).","PeriodicalId":137,"journal":{"name":"CA: A Cancer Journal for Clinicians","volume":"1 1","pages":"e70076"},"PeriodicalIF":254.7,"publicationDate":"2026-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147681554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrating multimodal management and molecular profiling in a patient with BRAF V600E–positive melanoma and brain metastases","authors":"David Gritsch MD, PhD, Riley M. Fadden CNP, Maura K. Mahar CNP, Melin J. Khandsekar MD, PhD, Kevin S. Oh MD. MBA, Daniel P. Cahil III MD, PhD, Gavin P. Dunn MD, PhD, Ryan J. Sullivan MD, Priscilla K. Brastianos MD","doi":"10.3322/caac.70079","DOIUrl":"10.3322/caac.70079","url":null,"abstract":"<p>A man in his late 20s was diagnosed with <i>BRAF V600E</i>-mutated cutaneous melanoma of the left knee (T3a) and underwent wide local excision. One year later, he had a solitary local recurrence resected and received 12 months of adjuvant dabrafenib and trametinib. Seven months after completion of adjuvant therapy, he developed headaches and a right visual field deficit. Magnetic resonance imaging (MRI) revealed a solitary left occipital enhancing lesion. Subtotal resection confirmed melanoma brain metastasis (MBM), and he initiated adjuvant ipilimumab/nivolumab, complicated by <i>Clostridiodies difficile</i> colitis and subsequent immune-related colitis requiring corticosteroids and vedolizumab. Postoperative radiotherapy (RT) was completed. Six months later, he underwent stereotactic radiosurgery (SRS) to a new left putamen lesion (hereinafter referred to as <i>basal ganglia lesion</i>). Nivolumab was resumed but discontinued because of severe inflammatory arthritis requiring immunosuppression.</p><p>The patient presented to our institution 6 months later. Positron emission tomography/computed tomography identified a new right thigh metastasis. MRI revealed apparent enlargement of the left occipital and basal ganglia lesions (Figure 1). Ipilimumab/nivolumab treatment was reinitiated but was complicated 3 months later by worsening right hemiparesis and hemianopia in the setting of hemorrhagic changes in both lesions. Stereotactic biopsy of the occipital lesion confirmed radiation necrosis. He subsequently developed acute worsening of right hemiparesis, and a lacunar infarct, attributed to mass effect on the lenticulostriate vessels, was identified. Given his biopsy-proven radiation necrosis and complete response of the right thigh metastasis, with no other systemic disease identified at the time, immunotherapy was discontinued (the last dose was received 3–4 weeks before biopsy).</p><p>Three months after the biopsy, resection of the enlarging occipital lesion was performed in the setting of worsening hemianopia and again confirmed radiation necrosis. One month later, the basal ganglia lesion showed further hemorrhagic progression and enlarging nodular enhancement with worsening edema, headaches, and aphasia. Surgical re-resection was not recommended. Multidisciplinary review concluded that, although radiation necrosis could not be excluded, a focal nodular region of enhancement raised concern for active tumor progression. Given diagnostic uncertainty and the need for rapid intracranial disease control, the team initiated encorafenib/binimetinib as the systemic therapy most likely to produce a prompt response and help distinguish tumor progression from radiation necrosis. Imaging 4 weeks later revealed reduced lesion size and edema. Over the following months, he was doing well clinically with only mild symptom burden and was able to work full time. After 7 months on targeted therapy, MRI revealed asymptomatic progression in the basal ganglia a","PeriodicalId":137,"journal":{"name":"CA: A Cancer Journal for Clinicians","volume":"76 2","pages":""},"PeriodicalIF":232.4,"publicationDate":"2026-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://acsjournals.onlinelibrary.wiley.com/doi/epdf/10.3322/caac.70079","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147518896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to “American Cancer Society’s report on the status of cancer disparities in the United States, 2025”","authors":"","doi":"10.3322/caac.70080","DOIUrl":"10.3322/caac.70080","url":null,"abstract":"<p>Islami F, Arias G, Lee D, et al. American Cancer Society’s Report on the Status of Cancer Disparities in the United States, 2025. <i>CA Cancer J Clin</i>. 2026;e70045. doi:10.3322/caac.70045</p><p>The data source for cancer survival data in the footnotes for Figure 3 and supplementary Figure S3 should be corrected to “Source: Surveillance, Epidemiology, and End Results 21 registries (excluding Illinois).” The published version was incorrectly listed as “Source: North American Association of Central Cancer Registries (estimates by race and ethnicity) and Surveillance, Epidemiology, and End Results 21 registries (excluding Illinois; estimates by urbanicity of county of residence).”</p><p>We apologize for this error.</p>","PeriodicalId":137,"journal":{"name":"CA: A Cancer Journal for Clinicians","volume":"76 2","pages":""},"PeriodicalIF":232.4,"publicationDate":"2026-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13004426/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147490239","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Aumolertinib with carboplatin–pemetrexed versus aumolertinib for nonsmall cell lung cancer with EGFR and concomitant tumor suppressor genes (ACROSS2): An open-label, multicenter, randomized phase 3 study","authors":"Jian-Chun Duan MD,&nbsp;Jia Zhong MD,&nbsp;Bo-Yang Sun MD,&nbsp;Wen-Hua Zhao MD,&nbsp;Lin Wu MD,&nbsp;Kai-Lun Fei MD,&nbsp;Qian Chu MD,&nbsp;Qi-Sen Guo MM,&nbsp;Qi-Bin Song MD,&nbsp;Yan Yu MD,&nbsp;Da-Xing Zhu MD,&nbsp;Xin-Yan Liu MD,&nbsp;Jun Zhao MD,&nbsp;Zhi-Xiang Zhan MB,&nbsp;Shi Li MB,&nbsp;Lei Nie MB,&nbsp;Jie Lin MM,&nbsp;Xiao-Dong Peng MD,&nbsp;Dian-Sheng Zhong MD,&nbsp;Jin Zhou MD,&nbsp;Li-Hua Li MD,&nbsp;Yun-Fang Chen MB,&nbsp;Chen Hu PhD,&nbsp;Tony Mok MD,&nbsp;Zhi-Jie Wang MD,&nbsp;Jie Wang MD","doi":"10.3322/caac.70071","DOIUrl":"10.3322/caac.70071","url":null,"abstract":"<p>Third-generation epidermal growth factor receptor–tyrosine kinase inhibitors (EGFR-TKIs) are standard first-line therapy for advanced, <i>EGFR</i>-mutated nonsmall cell lung cancer (NSCLC). However, their benefit is limited in patients who have co-existing tumor suppressor gene (TSG) mutations, highlighting a need for intensified strategies to improve outcomes. ACROSS2 (ClinicalTrials.gov identifier NCT04500717) is the first prospective, multicenter, randomized phase 3 study to compare the third-generation EGFR-TKI aumolertinib in combination with carboplatin–pemetrexed versus aumolertinib monotherapy in patients who had NSCLC with <i>EGFR</i> mutations and concomitant TSG mutations. In total, 126 patients were enrolled and randomly assigned to either combination therapy (<i>n</i> = 62) or monotherapy (<i>n</i> = 64). The primary end point was median progression-free survival (PFS). At a median follow-up of 25.3 months, combination therapy significantly prolonged median PFS compared with monotherapy (19.78 vs 16.53 months; hazard ratio, 0.58; 95% confidence interval, 0.34–0.97). Landmark PFS rates at 12, 18, and 24 months were 78.7% versus 65.3%, 67.2% versus 40.8%, and 41.0% versus 29.9%, respectively. Subgroup analyses demonstrated a clear PFS benefit in patients who had co-existing tumor protein p53 (<i>TP53</i>) mutations. Grade 3 or greater adverse events occurred in 25.9% of patients who received combination therapy versus 17.2% of those who received monotherapy; no drug-related deaths were observed. Overall survival data were immature (data maturity, 4%). The ACROSS2 trial provides the first prospective evidence supporting a genotype-directed, chemotherapy-targeted intensification approach favoring aumolertinib plus carboplatin–pemetrexed for this molecularly defined population.</p>","PeriodicalId":137,"journal":{"name":"CA: A Cancer Journal for Clinicians","volume":"76 2","pages":""},"PeriodicalIF":232.4,"publicationDate":"2026-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://acsjournals.onlinelibrary.wiley.com/doi/epdf/10.3322/caac.70071","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147439895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeting tumor suppressor gene co-mutations in EGFR-mutant nonsmall cell lung cancer: How ACROSS2 sharpens the case for early intensification","authors":"Krishna S. Gunturu MD,&nbsp;Hina Khan MD,&nbsp;Gilberto de Lima Lopes Jr MD, MBA","doi":"10.3322/caac.70072","DOIUrl":"10.3322/caac.70072","url":null,"abstract":"&lt;p&gt;The treatment landscape for &lt;i&gt;EGFR&lt;/i&gt;-mutated nonsmall cell lung cancer (NSCLC) continues to evolve with welcome speed. With the advent of third-generation tyrosine kinase inhibitors (TKIs) like osimertinib, treatment has improved systemic and central nervous system control. However, patients who have NSCLC harboring concomitant tumor suppressor gene alterations, particularly &lt;i&gt;TP53&lt;/i&gt; mutations, represent a biologically distinct subgroup with a poor prognosis and limited therapeutic options. TP53 co-mutations in &lt;i&gt;EGFR&lt;/i&gt;-mutated NSCLC range from 40% to 68% in the real-world setting. These &lt;i&gt;co-mutated&lt;/i&gt; tumors often behave aggressively, relapse earlier, and exhibit shorter lasting responses to targeted monotherapy.&lt;span&gt;&lt;sup&gt;1, 2&lt;/sup&gt;&lt;/span&gt; In one retrospective study, 5753 patients with &lt;i&gt;EGFR&lt;/i&gt;-mutant NSCLC specimens were molecularly profiled.&lt;span&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/span&gt; Patients younger than 50 years who had classical &lt;i&gt;EGFR&lt;/i&gt; mutations had the longest median overall survival (OS) with osimertinib compared with both older adults with classical &lt;i&gt;EGFR&lt;/i&gt; mutations (40 vs. 32 months; hazard ratio [HR], 0.692; &lt;i&gt;p&lt;/i&gt; &lt; .01) and older adults with atypical &lt;i&gt;EGFR&lt;/i&gt; mutations (40 vs. 21 months; HR, 0.47; &lt;i&gt;p&lt;/i&gt; &lt; .0001), independent of &lt;i&gt;TP53&lt;/i&gt; mutation status. However, compared with older adults (older than 50 years) with atypical &lt;i&gt;EGFR&lt;/i&gt; mutations, older adults with classical mutations had longer OS only in the absence of concurrent &lt;i&gt;TP53&lt;/i&gt; mutations (median OS, 39 vs. 28 months; HR, 0.735; &lt;i&gt;p&lt;/i&gt; &lt; .0001). In addition, &lt;i&gt;TP53&lt;/i&gt; co-mutations were enriched in the younger adult population (younger than 50 years; 76% vs. 62%, &lt;i&gt;q&lt;/i&gt; &lt; .05) compared with older adults.&lt;/p&gt;&lt;p&gt;One strategy to improve outcomes is upfront treatment intensification combining an &lt;i&gt;EGFR&lt;/i&gt; TKI and chemotherapy. Contemporary randomized phase 3 trials, specifically FLAURA2 and MARIPOSA (ClinicalTrials.gov identifiers NCT04035486 and NCT04487080, respectively), have established that upfront treatment intensification improves disease control beyond what can be achieved with TKI monotherapy alone. In this evolving therapeutic landscape, the prospective ACROSS2 trial (ClinicalTrials.gov identifier NCT03400717) adds important confirmatory evidence. Rather than redefining standards of care, the trial reinforces an emerging consensus across studies: early treatment intensification is associated with improved outcomes in most patients, and no clearly delineated subgroup has been identified for whom initial monotherapy is preferred.&lt;/p&gt;&lt;p&gt;In this issue of &lt;i&gt;CA: A Cancer Journal for Clinicians&lt;/i&gt;, investigators from the ACROSS2 phase 3 trial&lt;span&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/span&gt; offer a compelling, thoughtfully designed attempt to improve outcomes in advanced &lt;i&gt;EGFR&lt;/i&gt;-mutant NSCLC with tumor suppressor gene co-mutations. By selectively enrolling patients with &lt;i&gt;EGFR&lt;/i&gt; exon 19 deletion or L858R NSCLC who also harbor tumor suppressor ge","PeriodicalId":137,"journal":{"name":"CA: A Cancer Journal for Clinicians","volume":"76 2","pages":""},"PeriodicalIF":232.4,"publicationDate":"2026-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://acsjournals.onlinelibrary.wiley.com/doi/epdf/10.3322/caac.70072","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147439896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ethical considerations of genetic and genomic testing in pediatric oncology: A narrative review","authors":"Brittany L. Greene MD, MA,&nbsp;Jonathan M. Marron MD, MPH","doi":"10.3322/caac.70075","DOIUrl":"10.3322/caac.70075","url":null,"abstract":"<p>Genomics—and genomic testing in particular—has transformed oncology, facilitating both targeted therapies and personalized care. In pediatric oncology, unique clinical and ethical considerations arise. Compared with adults, children and adolescents are affected by more limited evidence regarding test performance, variant interpretation, and the clinical utility of genomically informed interventions. Nevertheless, genomic findings may have implications beyond the patient, affecting their parents, siblings, and other relatives and raising questions around consent, assent, privacy, and psychosocial impact. This narrative review examines how ethical dimensions of genetic and genomic testing evolve across the pediatric cancer continuum, from diagnosis and treatment through survivorship and transition to adult care. Attention is given to communication strategies, interdisciplinary support, and equity concerns that influence the responsible integration of genomic medicine. The authors also identify priority areas for future inquiry, including incorporation of children's perspectives, longitudinal approaches to recontact and reconsent, and better understanding of how genomic information affects treatment decision-making. Pediatric genetic and genomic testing in oncology holds great promise, but its benefits can only be realized through thoughtfully developed and standardized communication practices, careful ethical deliberation, and equitable implementation. By proactively addressing these issues, pediatric oncologists can harness genomic advances in ways that respect and support children and their families.</p>","PeriodicalId":137,"journal":{"name":"CA: A Cancer Journal for Clinicians","volume":"76 2","pages":""},"PeriodicalIF":232.4,"publicationDate":"2026-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12957712/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147346988","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Colorectal cancer statistics, 2026","authors":"Rebecca L. Siegel MPH,&nbsp;Nikita Sandeep Wagle MBBS, MHA, PhD,&nbsp;Jessica Star MA, MPH,&nbsp;Tyler B. Kratzer MPH,&nbsp;Robert A. Smith PhD,&nbsp;Ahmedin Jemal DVM, PhD","doi":"10.3322/caac.70067","DOIUrl":"10.3322/caac.70067","url":null,"abstract":"<p>Colorectal cancer (CRC) is the second most common cancer-related death in the United States and ranks first in adults younger than 50 years. Every 3 years, the American Cancer Society reports on CRC occurrence based on incidence from population-based cancer registries and mortality from the National Center for Health Statistics. Overall, CRC incidence declined by 0.9% annually during 2013–2022 driven by decreases of 2.5% annually in adults aged 65 years and older. In sharp contrast, incidence rates increased by 3% annually in adults aged 20–49 years and by 0.4% annually in adults aged 50–64 years dominated by tumors in the distal colon and rectum. Consequently, overall rectal cancer incidence increased by 1% annually from 2018 to 2022 after decades of decline and now accounts for 32% of all CRC, up from 27% in the mid-2000s. Increasing CRC incidence in adults aged 50–64 years was confined to regional and distant-stage diagnosis (1.1%–1.3% annually during 2013–2022), likely contributing to an upturn in mortality in this age group of 1% annually since 2019 that was steepest (2.3% annually) in White individuals. Mortality has increased in adults younger than 50 years by 1% annually since 2004, whereas rates have decreased in adults 65 years and older by 2.3% annually since 2012. Despite steady progress for older adults, both CRC incidence and mortality are increasing in adults younger than 65 years who are in the prime of life, underscoring an urgent need for etiologic research to discover the cause of the rising trend. Meanwhile, morbidity and mortality could be mitigated with earlier diagnosis, through screening and educating clinicians and the general public about CRC symptoms, and greater attention to the unique needs of younger patients, including discussion about the preservation of fertility and sexual health.</p>","PeriodicalId":137,"journal":{"name":"CA: A Cancer Journal for Clinicians","volume":"76 2","pages":""},"PeriodicalIF":232.4,"publicationDate":"2026-03-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12951547/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147324164","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adding carboplatin to sequential taxane-anthracycline neoadjuvant chemotherapy shows improved event-free and overall survival benefits in premenopausal women with triple-negative breast cancer.","authors":"Carrie Printz","doi":"10.3322/caac.70077","DOIUrl":"https://doi.org/10.3322/caac.70077","url":null,"abstract":"","PeriodicalId":137,"journal":{"name":"CA: A Cancer Journal for Clinicians","volume":"76 2","pages":"e70077"},"PeriodicalIF":232.4,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147721239","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiotherapy followed by adjuvant temozolomide improves survival for patients with aggressive IDH-mutated anaplastic glioma.","authors":"Carrie Printz","doi":"10.3322/caac.70078","DOIUrl":"10.3322/caac.70078","url":null,"abstract":"","PeriodicalId":137,"journal":{"name":"CA: A Cancer Journal for Clinicians","volume":"76 2","pages":"e70078"},"PeriodicalIF":232.4,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147721248","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global cancer statistics for children: Two decades of change and projections to 2050","authors":"Wangzhong Li MD,&nbsp;Shanzhou Huang MD,&nbsp;Qiyue Chen MD,&nbsp;Ting Wang MD,&nbsp;Guanming Lu MD,&nbsp;Xing Niu MD,&nbsp;Qiong Song MD,&nbsp;Yilin Xu MD,&nbsp;Ke Mo MD,&nbsp;Chunhui Cui MD,&nbsp;Run Zhang MD,&nbsp;Wei Du MD,&nbsp;Feiying He MD,&nbsp;Lei Shi MD,&nbsp;Yan Lin MD,&nbsp;Qiu Wei MD,&nbsp;Li Jiang MD,&nbsp;Yongsheng Chen MD,&nbsp;Baiyang Song MD,&nbsp;Huijuan Zhang MD,&nbsp;Zhenli Fu MD,&nbsp;Wenjing Liao MD,&nbsp;Jiancong Sun MD,&nbsp;Wenhui Guan MD,&nbsp;Weitao Zhuang MD,&nbsp;Nanshan Zhong MD,&nbsp;Chengzhi Zhou MD,&nbsp;Wenhua Liang MD,&nbsp;Min Kang MD,&nbsp;Jianxing He MD","doi":"10.3322/caac.70069","DOIUrl":"10.3322/caac.70069","url":null,"abstract":"<p>Reliable, contemporary estimates of the global childhood cancer burden remain scarce, particularly in the post-coronavirus disease 2019 (COVID-19) era. By using data from the Global Burden of Disease 2021 and Global Cancer Observatory 2022 projects, the authors evaluated the childhood cancer burden at global, regional, and national levels, characterizing temporal and projected trends, and analyzed the data according to disparities by geography and socioeconomic development. From 2000 to 2021, the age-standardized incidence rate (ASIR) and the age-standardized mortality rate (ASMR) of childhood cancer declined overall (average annual percent change, −0.88 and −2.13, respectively), especially during the COVID-19 pandemic. During this period, the disparities in childhood cancer burden were mainly concentrated in countries/territories with a lower Sociodemographic Index. In 2022, an estimated 202,164 new cases and 77,182 deaths from childhood cancer occurred worldwide (ASIR and ASMR, 10.3 and 3.9 per 100,000 children, respectively). Countries/territories with higher a Human Development Index (HDI) had a higher incidence (ASIR, 8.0 [low HDI] vs. 15.3 [very high HDI] per 100,000), whereas those with a lower HDI had higher mortality (ASMR, 4.4 [low HDI] vs. 2.8 [very high HDI] per 100,000). Analyses indicated that, by 2050, there will be 204,925 projected new cases and 78,210 deaths globally, with increases only in low HDI countries/territories, exacerbating existing health inequities. Childhood cancer remains a global health challenge, with notable geographic and socioeconomic disparities. These data serve as the impetus for governments and policymakers to prioritize resources and equitable access to interventions, particularly in regions with lower levels of development, while addressing health care vulnerabilities exposed by global crises like the COVID-19 pandemic.</p>","PeriodicalId":137,"journal":{"name":"CA: A Cancer Journal for Clinicians","volume":"76 2","pages":""},"PeriodicalIF":232.4,"publicationDate":"2026-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12947300/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147300143","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}